Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy: LYMPHOMA
Published in: Leukemia
Access to document
10.1038/s41375-025-02582-x
document
Over 60% of relapsed/refractory large B-cell lymphoma (R/R LBCL) patients treated with chimeric antigen receptor (CAR) T-cells experience progressive disease. The impact of site-specific extranodal involvement on CAR-T outcomes has not been fully elucidated. This multicenter study included 516 R/R LBCL patients infused with CD19-targeted CAR T-cells; 177 (34%) had only-nodal (N), 66 (13%) only-extranodal (E) and 273 (53%) nodal and extranodal (NE) disease at time of CAR T-cells. The NE cohort included more patients with a poor performance status and high tumor burden. In the multivariable analysis,...
Gloria Iacoboni, Kai Rejeski, Víctor Navarro, Tom van Meerten, Alex Rampotas, Ana África Martín-López, Mariana Bastos, Ana Benzaquén, Juan Luis Reguera-Ortega, Cecilia Carpio, Claire Roddie, Lucia López-Corral, Javier Delgado-Serrano, Maria Landwehr, Sophia Stock, Pablo Silva de Tena, Pau Abrisqueta, Janneke de Boer, Alejandro Martin Garcia-Sancho, Rafael HernaniMi Kwon, Marion Subklewe, Maeve O’Reilly, Pere Barba
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Published in: The Lancet Oncology
Access to document
10.1016/S1470-2045(24)00682-X
document
Background: The combination of ibrutinib and venetoclax leverages complementary mechanisms of action and has shown promising clinical activity in mantle cell lymphoma (MCL). This study evaluated the efficacy and safety of ibrutinib–venetoclax compared with ibrutinib–placebo in patients with relapsed or refractory MCL. Methods: SYMPATICO is a multicentre, randomised, double-blind, placebo-controlled, phase 3 study performed at 84 hospitals in Europe, North America, and Asia–Pacific. Eligible patients were adults (aged ≥18 years) with pathologically confirmed relapsed or refractory MCL after one to five previous lines of therapy and an Eastern...
Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer-Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam
Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months
Published in: European Journal of Haematology
Access to document
10.1111/ejh.70003
document
Chimeric antigen receptor T-cell therapy (CART) has replaced salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) as the preferred second-line treatment for early relapsed (< 12 months) large B-cell lymphoma (LBCL). However, for patients with a late relapse (> 12 months), CART is inaccessible until third line. We analyzed 877 patients from the HemoBase registry (diagnosed 2005-2020) to assess differences in long-term outcomes of early versus late relapse in second line. Early relapse occurred in 120/654 patients (18%) who completed first-line treatment, with 2- and 5-year overall survival...
HemoBase Population Registry Consortium, Hilde T van der Galiën, Hilde A M Kooistra, Robby Kibbelaar, Nic J G M Veeger, Marcel Nijland, Gerwin Huls, Tom van Meerten, Rozemarijn S van Rijn
Facts and hopes for PET imaging-derived immunotherapy biomarkers
Published in: Clinical Cancer Research
Access to document
10.1158/1078-0432.CCR-24-1427
document
Current immunotherapies have brought major progress in cancer treatments, but not all patients benefit. Therefore, insight into reasons for treatment failure and optimal biomarkers for patient selection are warranted. Current approved biomarkers for cancer immunotherapy do not provide insight into characteristics across tumor lesions in a patient or their heterogeneity. Here, whole-body positron emission tomography (PET) imaging with specific tracers may provide support. Moreover, the biodistribution of cell therapies and complex molecules, such as bispecific antibodies, can be visualized by PET imaging, and repeat PET imaging allows to...
High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring
Published in: Endocrine practice
Access to document
10.1016/j.eprac.2024.09.013
document
OBJECTIVES: During intensive hematological care, patients are exposed to high-dose chemotherapy, corticosteroids, immunosuppressants and total parenteral nutrition. Combined with physiological stress and increased release of cytokines and hormones, this can lead to dysglycemia, which is associated with adverse clinical outcomes. This prospective study aims to investigate continuous glucose monitoring (CGM) to identify dysglycemia during intensive hematological care. METHODS: Patients receiving chimeric antigen receptor (CAR) T-cell therapy, allogeneic or autologous stem cell transplantation (SCT) were eligible. Throughout the study, glucose levels were concurrently monitored using CGM and point-of-care (POC)...